How Long to Treat with Denosumab
Current Osteoporosis Reports
|October 18, 2015
Summary
Long-term treatment with denosumab effectively prevents fractures in osteoporosis patients. Denosumab (fully human monoclonal antibody) shows a favorable safety profile for high-risk individuals.
Area of Science:
- Bone biology and pharmacology
- Endocrinology and metabolic bone diseases
- Rheumatology and immunology
Background:
- Osteoporosis is a chronic condition characterized by increased fracture risk.
- Effective long-term management is crucial for preventing fragility fractures.
- Denosumab targets RANK ligand, a key mediator of bone resorption.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of denosumab in osteoporosis.
- To assess the benefit profile of denosumab for high-risk fracture patients.
Main Methods:
- Review of clinical trial data on denosumab in osteoporosis.
- Analysis of long-term treatment outcomes and safety profiles.
Main Results:
- Denosumab demonstrated long-term effectiveness in preventing fractures.
- The treatment exhibited an excellent safety profile in clinical trials.
- Positive benefit-risk assessment for long-term denosumab therapy.
Conclusions:
- Long-term denosumab treatment is effective for osteoporosis management.
- Denosumab offers an attractive benefit profile for patients at high risk of fracture.
- Continued research supports denosumab's role in chronic bone disease treatment.
More Related Videos
08:05Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
Published on: December 9, 2022
5.3K
10:13Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
Published on: June 21, 2022
2.7K
Related Concept Videos
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
89
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
89
01:01Dosage Regimen: Fixed Dose
2.5K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.5K
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
350
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
350
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
92
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
92
01:11Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
925
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
925
01:20Myasthenia Gravis: Overview and Treatment
3.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.4K